The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
The serial acquirer of royalty interests is coming into its own, but the secret to its success lies in cystic fibrosis.
Meanwhile, Royalty Pharma bets that Trelegy will do better than the sellside expects.
Yesterday’s takeout of Teneotwo came amid notable big pharma interest in the geeky science behind heavy chain-only antibodies.
M&A is back on the menu, but there are still reasons to be cautious.